PH12019500731A1 - Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors - Google Patents
Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitorsInfo
- Publication number
- PH12019500731A1 PH12019500731A1 PH12019500731A PH12019500731A PH12019500731A1 PH 12019500731 A1 PH12019500731 A1 PH 12019500731A1 PH 12019500731 A PH12019500731 A PH 12019500731A PH 12019500731 A PH12019500731 A PH 12019500731A PH 12019500731 A1 PH12019500731 A1 PH 12019500731A1
- Authority
- PH
- Philippines
- Prior art keywords
- ring system
- bicyclic ring
- system substituted
- prmt5 inhibitors
- novel
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000002950 monocyclic group Chemical group 0.000 title abstract 2
- 101150097768 prmt5 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403336P | 2016-10-03 | 2016-10-03 | |
| EP17157785 | 2017-02-24 | ||
| PCT/EP2017/074983 WO2018065365A1 (en) | 2016-10-03 | 2017-10-02 | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019500731A1 true PH12019500731A1 (en) | 2019-06-24 |
Family
ID=60043171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019500731A PH12019500731A1 (en) | 2016-10-03 | 2019-04-03 | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11098062B2 (enExample) |
| EP (1) | EP3519413A1 (enExample) |
| JP (2) | JP7101171B2 (enExample) |
| KR (1) | KR102531344B1 (enExample) |
| CN (2) | CN109803971B (enExample) |
| AU (1) | AU2017338269B2 (enExample) |
| BR (1) | BR112019006414A2 (enExample) |
| CA (1) | CA3037998A1 (enExample) |
| IL (1) | IL265718B (enExample) |
| MA (1) | MA46341A (enExample) |
| MX (2) | MX2019003843A (enExample) |
| PE (1) | PE20190706A1 (enExample) |
| PH (1) | PH12019500731A1 (enExample) |
| TN (1) | TN2019000087A1 (enExample) |
| UA (1) | UA124074C2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| AU2017338269B2 (en) | 2016-10-03 | 2021-03-25 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| WO2018154104A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| BR112020010815A2 (pt) | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
| WO2019219805A1 (en) * | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| EP4031555A1 (en) * | 2019-09-18 | 2022-07-27 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| CN115135651A (zh) * | 2019-12-03 | 2022-09-30 | 鲁皮恩有限公司 | 作为prmt5抑制剂的被取代的核苷类似物 |
| CN113186153B (zh) * | 2021-04-15 | 2023-09-08 | 南方医科大学 | Prmt5抑制剂在促进精原干细胞损伤再生和增殖中的应用 |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| CN114740108B (zh) * | 2022-03-28 | 2023-07-14 | 天津键凯科技有限公司 | 一种聚合物修饰抗体类药物的修饰度的测定方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| US7144871B2 (en) | 2002-02-19 | 2006-12-05 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2005005450A1 (ja) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | 環状ビスジヌクレオシドの合成方法 |
| AU2004311702A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| SG181703A1 (en) | 2009-12-18 | 2012-07-30 | Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| US9029343B2 (en) | 2010-12-03 | 2015-05-12 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2651885A1 (en) | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Anti-viral compounds |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| JO3154B1 (ar) | 2011-06-17 | 2017-09-20 | Glaxosmithkline Llc | عوامل مضادة لـ trpv4 |
| JP2014530910A (ja) | 2011-10-24 | 2014-11-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | 新規化合物 |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| EP2975938A4 (en) | 2013-03-15 | 2017-02-15 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| NZ728162A (en) | 2014-07-01 | 2023-06-30 | Takeda Pharmaceuticals Co | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| CN107278205A (zh) | 2015-02-24 | 2017-10-20 | 辉瑞大药厂 | 用作抗癌药的取代的核苷衍生物 |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| AU2017338269B2 (en) | 2016-10-03 | 2021-03-25 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018154104A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| BR112020010815A2 (pt) | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
-
2017
- 2017-10-02 AU AU2017338269A patent/AU2017338269B2/en active Active
- 2017-10-02 MX MX2019003843A patent/MX2019003843A/es unknown
- 2017-10-02 CN CN201780061258.4A patent/CN109803971B/zh active Active
- 2017-10-02 PE PE2019000723A patent/PE20190706A1/es unknown
- 2017-10-02 UA UAA201904546A patent/UA124074C2/uk unknown
- 2017-10-02 US US16/336,934 patent/US11098062B2/en active Active
- 2017-10-02 KR KR1020197012099A patent/KR102531344B1/ko active Active
- 2017-10-02 BR BR112019006414A patent/BR112019006414A2/pt active Search and Examination
- 2017-10-02 MA MA046341A patent/MA46341A/fr unknown
- 2017-10-02 CN CN202211277466.7A patent/CN115626935B/zh active Active
- 2017-10-02 JP JP2019517909A patent/JP7101171B2/ja active Active
- 2017-10-02 TN TNP/2019/000087A patent/TN2019000087A1/en unknown
- 2017-10-02 EP EP17781060.3A patent/EP3519413A1/en active Pending
- 2017-10-02 CA CA3037998A patent/CA3037998A1/en active Pending
-
2019
- 2019-03-31 IL IL265718A patent/IL265718B/en unknown
- 2019-04-02 MX MX2023005574A patent/MX2023005574A/es unknown
- 2019-04-03 PH PH12019500731A patent/PH12019500731A1/en unknown
-
2021
- 2021-07-16 US US17/378,417 patent/US11993614B2/en active Active
-
2022
- 2022-03-04 JP JP2022033419A patent/JP7576587B2/ja active Active
-
2023
- 2023-10-17 US US18/488,626 patent/US20240124493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA46341A (fr) | 2019-08-07 |
| US20190263833A1 (en) | 2019-08-29 |
| US20240124493A1 (en) | 2024-04-18 |
| US11098062B2 (en) | 2021-08-24 |
| AU2017338269B2 (en) | 2021-03-25 |
| IL265718A (en) | 2019-05-30 |
| CN115626935B (zh) | 2025-07-15 |
| BR112019006414A2 (pt) | 2019-06-25 |
| JP2022084699A (ja) | 2022-06-07 |
| MX2023005574A (es) | 2023-05-29 |
| MX2019003843A (es) | 2019-06-24 |
| JP7576587B2 (ja) | 2024-10-31 |
| US11993614B2 (en) | 2024-05-28 |
| JP2019534255A (ja) | 2019-11-28 |
| CN109803971B (zh) | 2022-10-28 |
| TN2019000087A1 (en) | 2020-07-15 |
| US20210371433A1 (en) | 2021-12-02 |
| CN109803971A (zh) | 2019-05-24 |
| KR20190056425A (ko) | 2019-05-24 |
| AU2017338269A1 (en) | 2019-04-04 |
| CN115626935A (zh) | 2023-01-20 |
| PE20190706A1 (es) | 2019-05-17 |
| UA124074C2 (uk) | 2021-07-14 |
| KR102531344B1 (ko) | 2023-05-10 |
| JP7101171B2 (ja) | 2022-07-14 |
| EP3519413A1 (en) | 2019-08-07 |
| IL265718B (en) | 2021-08-31 |
| CA3037998A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005182A (es) | Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5. | |
| PH12019500731A1 (en) | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors | |
| EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2020005944A (es) | Analogos espirobiciclicos novedosos. | |
| NZ725399A (en) | Macrocylic pyrimidine derivatives | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX2016012994A (es) | Derivados de piridina macrociclicos. | |
| MX378732B (es) | Formas solidas novedosas | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| MX382601B (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
| PH12018501895A1 (en) | Substituted nucleoside analogues for use as prmt5 inhibitors |